<DOC>
	<DOCNO>NCT01066234</DOCNO>
	<brief_summary>This study propose adjuvant concurrent chemoradiotherapy v chemotherapy alone completely resect microscopic N2 NSCLC</brief_summary>
	<brief_title>Adjuvant CCRT v CT Minimal N2 NSCLC</brief_title>
	<detailed_description>Approximately 15 % patient non-small cell lung cancer diagnose stage IIIA-N2 disease . However , subgroup heterogeneous , lymph node microscopically invade radiologically visible bulky ipsilateral mediastinal lymph node involvement . Surgical resection select patient result 5-year survival rate 7-24 % . The standard treatment locally advance clinical N2 disease definitive concurrent chemoradiotherapy induction chemotherapy ( ± radiation ) follow operation . However , patient , N2 status could confirm curative operation without evidence N2 diseases preoperative evaluation method ( CT , PET , mediastinoscopy ) . We usually define N2 disease find curative operation microscopic N2 , adjuvant chemotherapy , radiotherapy concurrent chemoradiotherapy . However , little data adjuvant therapy completely resect N2 disease available , Hence , propose randomize phase II study adjuvant concurrent chemoradiotherapy v chemotherapy alone completely resect microscopic N2 NSCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Histologically confirm diagnosis stage IIIA ( N2 ) NSCLC completely resect lobectomy , bilobectomy , pneumonectomy , sleeve lobectomy incision ( thoracoscopic videoassisted thorascopic surgery approach acceptable ) 2 . `` Pathologic N2 '' disease ( involvement N2 node determine time surgical exploration postoperative pathologic analysis ) 3 . Age ≥18years 4 . No known residual disease ( negative resection margin extracapsular invasion lymph node metastasis ) 5 . ECOG performance status 0 1 6 . No previous chemotherapy RT 7 . Adequate organ function evidence follow ; Absolute neutrophil count &gt; 1.5 x 109/L ; platelet &gt; 100 x 109/L ; total bilirubin ≤1.5 UNL ; AST and/or ALT &lt; 5 UNL ; creatinine clearance ≥ 50mL/min 8 . Written inform consent form 1 . Patients preoperative mediastinoscopic N2 positive disease 2 . Uncontrolled systemic illness DM , CHF , unstable angina , hypertension arrhythmia 3 . Patients postobstructive pneumonia uncontrolled serious infection 4 . Pregnant nursing woman ( Women reproductive potential agree use effective contraceptive method ) 5 . Prior history malignancy within 5 year study entry except adequately treat basal cell squamous cell skin cancer situ cervical cancer , welltreated thyroid cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Microscopic N2 Non-small Cell Lung Cancer</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Cisplatin</keyword>
</DOC>